Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PRAME family member 12 (PRAMEF12)
- Target
- PRAMEF12
- Molecular classification
- Cancer/testis antigen, Leucine-rich repeat protein, Other
01
Overview
PRAME family member 12 (PRAMEF12) is a protein-coding gene belonging to the cancer/testis antigen family, characterized by leucine-rich repeat motifs[2][3]. PRAMEF12 is normally expressed in testis and abnormally activated in several types of cancers, especially gliomas, where it promotes proliferation and inhibits apoptosis[2]. It plays a significant role in the maintenance of the spermatogenic lineage, being expressed in undifferentiated spermatogonia[4]. Knockdown of PRAMEF12 leads to suppressed tumor cell proliferation, increased apoptosis, and S-phase cell cycle arrest[2]. Its high expression in cancers, particularly glioma, provides utility as a diagnostic biomarker and a potential immunotherapeutic target. No direct drug interactions or approved therapies currently target PRAMEF12, and more research is needed to fully characterize its molecular partners and clinical potential[2][5].
- Other names
- PRAMEF12OTTHUMG00000001927PRAME family member 12, PRAMEF12
02
Biological functions
Cell proliferationRegulation of cell cycleInhibition of apoptosisSpermatogenesisNegative regulation of Wnt signaling pathwayOther
03
Disease associations
Cancer (notably glioma and other tumors)Spermatogenic failure/infertilityNeurodegenerative disease (link to Huntington’s disease is described but not fully established)
04
Safety considerations
Expression mainly in tumors and testis suggests low off-tumor on-target toxicity risk for immunotherapy, but normal testis expression may pose infertility risks[4][2]
05
Biomarkers
Diagnostic biomarker for gliomaPossibly used for tumor antigen-based immunotherapy approaches[2]
Beyond the preview
Go deeper on PRAME family member 12 (PRAMEF12).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRAME family member 12 (PRAMEF12).